aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies
March 20, 2023 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, March 20, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its...
aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update
March 09, 2023 16:00 ET
|
aTyr Pharma, Inc.
Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis enrolling in the U.S., Europe and Japan. Phase 2 proof-of-concept study of efzofitimod in patients with SSc-ILD expected...
aTyr Pharma to Present at March Investor Conferences
March 08, 2023 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
Independent Preliminary Economic Assessment for Atlas Salt’s Great Atlantic Project Supports State-of-the-Art “Salt Factory” Vision
January 30, 2023 20:24 ET
|
Atlas Salt Inc.
ST. JOHN’S, Newfoundland and Labrador, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Atlas Salt (the “Company” or “Atlas” – TSXV: SALT; OTCQB: REMRF) is pleased to announce the results of an independent...
aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis
January 19, 2023 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
Atlas Salt Announces Institutionally Targeted Strategic Private Placement for Up to $10 Million
January 12, 2023 18:15 ET
|
Atlas Salt Inc.
ST. JOHN’S, Newfoundland and Labrador, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Atlas Salt (the “Company” or “Atlas” - TSXV: SALT; OTCQB: REMRF), 100% owner of North America’s premier undeveloped...
aTyr Pharma Announces LTBP1 as Target of DARS tRNA Synthetase Fragment
December 15, 2022 08:00 ET
|
aTyr Pharma, Inc.
LTBP1 is key regulator of TGF-β, a major driver of fibrosis. Latest target identified from company’s platform in collaboration with Dualsystems Biotech AG. SAN DIEGO, Dec. 15, 2022 (GLOBE...
Atlas Salt Nears Economic Analysis for Great Atlantic
December 08, 2022 17:21 ET
|
Atlas Salt Inc.
ST. JOHN’S, Newfoundland and Labrador, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Atlas Salt (the “Company” or “Atlas” - TSXV: SALT) is pleased to provide the following update on its 100%-owned Great...
Compass Minerals Class Action Deadline Alert: Johnson Fistel, Globally-Recognized Law Firm Encourages Shareholders to Submit Their CMP Losses
December 01, 2022 07:06 ET
|
Johnson Fistel, LLP
SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Compass Minerals...
Life Reinsurance Market Size In 2022 (New Report) | No. of pages: 115|: Manufacturers Data, Opportunity, Import Export Scenario, Application, Type, Regions and Future Forecast till 2028 with Top Growth Companies
November 16, 2022 02:12 ET
|
Proficient Market Insights
Pune, Nov. 16, 2022 (GLOBE NEWSWIRE) -- "Life Reinsurance Market" research report focus on overall information that can help to take decisions on current market situation. Reinsurance, also known as...